Genmab A/S
Genmab is a Denmark-based biotechnology company developing innovative antibody therapeutics through proprietary antibody-science platforms and collaborations. Its research emphasizes treatments for cancer and other serious diseases and extends from therapeutic discovery into clinical development and commercialization. Its official company pages describe multiple proprietary technologies, while its annual report documents the issuer across Nasdaq Copenhagen and the Nasdaq US market under GMAB. The directory treats the dual listings as one corporate entity.
Company at a glance
Corporate information
- Company entity
- Genmab A/S
- Headquarters / principal office
- Denmark
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://genmab.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Copenhagen: GMAB Nasdaq: GMAB
therapeutic-antibodies · bispecific-antibodies · antibody-platforms
oncology · serious-diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Genmab is a Denmark-based biotechnology company developing innovative antibody therapeutics through proprietary antibody-science platforms and collaborations. Its research emphasizes treatments for cancer and other serious diseases and extends from therapeutic discovery into clinical development and commercialization. Its official company pages describe multiple proprietary technologies, while its annual report documents the issuer across Nasdaq Copenhagen and the Nasdaq US market under GMAB. The directory treats the dual listings as one corporate entity.
Business, technology & evidence
- SecuritiesNasdaq Copenhagen: GMAB / Nasdaq: GMAB
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Genmab A/S ↗Genmab A/S ·
- Official issuer and R&D disclosure · Genmab A/S ↗Genmab A/S ·
- Official issuer and R&D disclosure · Genmab A/S ↗Genmab A/S ·
- Official issuer and R&D disclosure · Genmab A/S ↗Genmab A/S ·
- Official issuer and R&D disclosure · Genmab A/S ↗Genmab A/S ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.